ERBB2 and gastric cancer: In conclusion, HER2 is a promising therapeutic target, and although many HER2-targeted drugs are available, the treatment efficiency in patients with advanced GC is low, and the survival benefit is not satisfactory due to the high heterogeneity of GC and the development of resistance.